Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

Case report: Sotrovimab, remdesivir and nirmatrelvir/ritonavir combination as salvage treatment option in two immunocompromised patients hospitalized for COVID-19

COVID-19 in immunocompromised patients is difficult to treat. SARS-CoV-2 interaction with the host immune system and the role of therapy still remains only partly understood. There are no data regarding the use of monoclonal antibodies and the combination of two antivirals in fighting viral replicat...

Full description

Bibliographic Details
Main Authors: Federico Baldi, Chiara Dentone, Malgorzata Mikulska, Daniela Fenoglio, Michele Mirabella, Federica Magnè, Federica Portunato, Tiziana Altosole, Chiara Sepulcri, Daniele Roberto Giacobbe, Chiara Uras, Graziana Scavone, Lucia Taramasso, Andrea Orsi, Giuseppe Cittadini, Gilberto Filaci, Matteo Bassetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Medicine
Subjects:
salvage therapy
COVID-19
immunocompromised
monoclonal antibodies
sotrovimab
nirmatrelvir/ritonavir
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2022.1062450/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2022.1062450/full

Similar Items